[1] Thomas, G. (2012) Química Medicinal: uma introdução. Guanabara Koogan, São Paulo.
[2] Barreiro, E.J. (2008) As Bases Moleculares da Ação dos Fármacos. 2th Edition, C.A.M, Porto Alegre.
[3] Fraga, C.A.M. and Barreiro, E.J. (1996) Cardiotônicos: histórico e perspectivas de uma importante classe de agentes terapêuticos. Quimica Nova, 19, 182-189.
[4] Kubinyi, H. (1977) Quantitative Structure-Activity Relations. 7. The Bilinear Model, a New Model for Nonlinear Dependence of Biological Activity on Hydrophobic Character. Journal of Medicinal Chemistry, 20, 625-629. http://dx.doi.org/10.1021/jm00215a002
[5] Lombardo, F., Lipinski, C.A., Dominy, B.W. and Feeney, P.J. (1997) Experimental and Computational Approaches to Estimate Solubility and Permeability in Drug Discovery and Development Setting. Advanced Drug Delivery Reviews, 23, 3-25. http://dx.doi.org/10.1016/S0169-409X(96)00423-1
[6] http://www.molinspiration.com
[7] http://www.molsoft.com/servers.html
[8] Connolly, D.J., Cusack, D., O’Sullivan, T.P. and Guiry, P.J. (2005) Synthesis of Quinazolinones and Quinazolines. Tetrahedron, 61, 10153-10202. http://dx.doi.org/10.1016/j.tet.2005.07.010
[9] Katritzky, A.R. and Pozharskii, A.F. (2003) Handbook of Heterocyclic Chemistry. Pergamon Press, Oxford.
[10] Mhaske, S.B. and Argade, N.P. (2006) The Chemistry of Recently Isolated Naturally Occurring Quinazolinone Alkaloids. Tetrahedron, 62, 9787-9826. http://dx.doi.org/10.1016/j.tet.2006.07.098
[11] Bridges, A.J., Zhou, H., Cody, D.R., Rewcastle, G.W., McMichael, A., Showalter, H.D., Fry, D.W., Kraker, A.J. and Denny, W.A.T. (1996) Tyrosine Kinase Inhibitors. 8. An Unusually Steep Structure-Activity Relationship for Analogues of 4-(3-Bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a Potent Inhibitor of the Epidermal Growth Factor Receptor. Journal of Medicinal Chemistry, 39, 267-276.
http://dx.doi.org/10.1021/jm9503613
[12] Rahman, M.U., Rathore, A., Siddiqui, A.A., Parveen, G. and Yar, M.S. (2014) Synthesis and Characterization of Quinazoline Derivatives: Search for Hybrid Molecule as Diuretic and Antihypertensive Agents. Journal of Enzyme Inhibition and Medicinal Chemistry, 29, 733-743.
http://dx.doi.org/10.3109/14756366.2013.845820
[13] Matsuda, H., Yoshikawa, M., Ko, S., Iinuma, M. and Kubo, M. (1998) Antinociceptive and Anti-Inflammatory Activities of Evodiamine and Rutaecarpine. Nature Medicine, 52, 203-208.
[14] Buchanan, J.G. and Sable, H.Z. (1972) Selective Organic Transformations. Wiley-Interscience, New York.
[15] Hibino, S. and Choshi, T. (2001) Simple Indole Alkaloids and Those with a Nonrearranged Monoterpenoid Unit. Natural Product Reports, 18, 66-87. http://dx.doi.org/10.1039/b004055j
[16] Koepfly, J.B., Mead, J.F. and Brockman Jr., J.A. (1947) An Alkaloid with High Antimalarial Activity from Dichroa febrifuga. Journal of the American Chemical Society, 69, 1837-1837.
http://dx.doi.org/10.1021/ja01199a513
[17] Kacker, I.K. and Zaheer, S.H. (1951) Synthesis of Substituted 4-Quinazolones. Journal of Indian Chemical Society, 28, 344-346.
[18] Amin, A.H., Mehta, D.R. and Samarth, S.S. (1970) Biological Activity in the Quinazolone Series. Progress in Drug Research, 14, 218-268. http://dx.doi.org/10.1007/978-3-0348-7075-7_5
[19] Fry, D.W., Kraker, A.J., McMichael, A., Ambroso, L.A., Nelson, J.M., Leopold, W.R., Connors, R.W. and Bridges, A.J. (1994) A Specific Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase. Science, 265, 1093-1095. http://dx.doi.org/10.1126/science.8066447
[20] Baselga, J. (2006) Targeting Tyrosine Kinases in Cancer: The Second Wave. Science, 312, 1175-1178.
http://dx.doi.org/10.1126/science.1125951
[21] Rewcastle, G.W., Denny, W.A., Bridges, A.J., Zhou, H., Cody, D.R., McMichael, A. and Fry, D.W. (1995) Tyrosine Kinase Inhibitors. Synthesis and Structure-Activity Relationships for 4-[(Phenylmethyl)amino] and 4-(Phenylamino) Quinazolines as Potent Adenosine 5’-Triphosphate Binding Site Inhibitors of the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor. Journal of Medicinal Chemistry, 38, 3482-3487.
http://dx.doi.org/10.1021/jm00018a008
[22] Levitzki, A. (2003) Protein Kinase Inhibitors as a Therapeutic Modality. Accounts of Chemical Research, 36, 462-469. http://dx.doi.org/10.1021/ar0201207
[23] Vansteenkiste, J.F. (2004) Gefitinib (Iressa): A Novel Treatment for Non-Small Cell Lung Cancer. Expert Review of Anticancer Therapy, 4, 5-17. http://dx.doi.org/10.1586/14737140.4.1.5
[24] Bonomi, P. (2003) Erlotinib: A New Therapeutic Approach for Non-Small Cell Lung Cancer. Expert Opinion on Investigational Drugs, 12, 1395-1401. http://dx.doi.org/10.1517/13543784.12.8.1395
[25] Gilmer, T.M., Cable, L., Alligood, K., Rusnak, D., Spehar, G., Gallagher, K.T., Woldu, E., Carter, H.L., Truesdale, A.T., Shewchuk, L. and Wood, E.R. (2008) Impact of Common Epidermal Growth Factor Receptor and HER2 Variants on Receptor Activity and Inhibition by Lapatinib Wood. Cancer Research, 68, 571-579. http://dx.doi.org/10.1158/0008-5472.CAN-07-2404
[26] Traxler, P. (2003) Tyrosine Kinases as Targets in Ancer Therapy—Successes and Failures. Expert Opinion on Therapeutic Targets, 7, 215-234. http://dx.doi.org/10.1517/14728222.7.2.215
[27] Vema, A., Panigrahi, S.K., Rambabu, G., Gopalakrishinan, B., Sarma, J.A.R.P. and Desiraju, G.R. (2003) Design of EGFR Kinase Inhibitors: A Ligand Based Approach and Its Confirmation with Structure Based Studies. Bioorganic & Medicinal Chemistry, 11, 4643-4653.
http://dx.doi.org/10.1016/s0968-0896(03)00482-6
[28] Golan, D.E. (2009) Principles of Pharmacology. 2nd Edition, Medicine & Health Science Books, New York.
[29] Howland, R.D. and Mycek, M.J. (2008) Farmacologia Ilustrada. 3rd Edition, Artmed, São Paulo.
[30] García-Echeverría, C., Traxler, P. and Evans, D.B. (2000) ATP Site-Directed Competitive and Irreversible Inhibitors of Protein Kinases. Medicinal Research Reviews, 20, 28-57.
http://dx.doi.org/10.1002/(SICI)1098-1128(200001)20:1<28::AID-MED2>3.0.CO;2-2
[31] ACD/Labs Release 2012 (File Version 14.01, Build 65894), 17 Sep. 2013. www.acdlabs.com